



NEONATAL

CEFTAZIDIME




This document should be read in conjunction with this [DISCLAIMER](#)

Restricted: Requires Neonatologist/Microbiologist review within 24 hours of initiation

Presentation	Vial: 1g (1000mg)																																		
Classification	Anti-infective: Third Generation Cephalosporin																																		
Indication	Used to treat infections caused by susceptible organisms with suspected resistance to other antimicrobials Treatment of pseudomonas organisms resistant to, or as an alternative to aminoglycosides.																																		
Dose	<p>Dose : 30mg/kg/dose Maximum daily dose 150mg/kg/day Dose Intervals (frequency) varies according to corrected gestational age.</p> <table border="1"> <thead> <tr> <th>Corrected Gestational Age (CGA)</th> <th>Postnatal Age</th> <th>Frequency</th> </tr> </thead> <tbody> <tr> <td rowspan="2">≤29 weeks</td> <td>0-28 days</td> <td>Every 12 hours</td> </tr> <tr> <td>>28 days</td> <td>Every 8 hours</td> </tr> <tr> <td rowspan="2">30-36 weeks</td> <td>0-14 days</td> <td>Every 12 hours</td> </tr> <tr> <td>>14 days</td> <td>Every 8 hours</td> </tr> <tr> <td rowspan="2">37-44 weeks</td> <td>0-7 days</td> <td>Every 12 hours</td> </tr> <tr> <td>>7 days</td> <td>Every 8 hours</td> </tr> <tr> <td>≥45 weeks</td> <td>ALL ages</td> <td>Every 8 hours</td> </tr> </tbody> </table> <p>Severe Infections Consult microbiology</p> <table border="1"> <thead> <tr> <th>CGA</th> <th>Postnatal Age</th> <th>Dose</th> <th>Frequency</th> </tr> </thead> <tbody> <tr> <td rowspan="2">ALL</td> <td>0-7 days</td> <td>50mg/kg</td> <td>Every 12 hours</td> </tr> <tr> <td>>7 days</td> <td>50mg/kg</td> <td>Every 8 hours</td> </tr> </tbody> </table>			Corrected Gestational Age (CGA)	Postnatal Age	Frequency	≤29 weeks	0-28 days	Every 12 hours	>28 days	Every 8 hours	30-36 weeks	0-14 days	Every 12 hours	>14 days	Every 8 hours	37-44 weeks	0-7 days	Every 12 hours	>7 days	Every 8 hours	≥45 weeks	ALL ages	Every 8 hours	CGA	Postnatal Age	Dose	Frequency	ALL	0-7 days	50mg/kg	Every 12 hours	>7 days	50mg/kg	Every 8 hours
Corrected Gestational Age (CGA)	Postnatal Age	Frequency																																	
≤29 weeks	0-28 days	Every 12 hours																																	
	>28 days	Every 8 hours																																	
30-36 weeks	0-14 days	Every 12 hours																																	
	>14 days	Every 8 hours																																	
37-44 weeks	0-7 days	Every 12 hours																																	
	>7 days	Every 8 hours																																	
≥45 weeks	ALL ages	Every 8 hours																																	
CGA	Postnatal Age	Dose	Frequency																																
ALL	0-7 days	50mg/kg	Every 12 hours																																
	>7 days	50mg/kg	Every 8 hours																																

Compatible Fluids	Glucose 5%, Glucose 10%, Sodium Chloride 0.9%
Preparation	<p>IV: Available from CIVAS (KEMH & PCH)</p> <p>IV Injection</p> <ul style="list-style-type: none"> • Reconstitute the vial (1g) with 9.4mL of Water for Injections • Shake to dissolve. The solution will fizz and become clear in 1 to 2 minutes. • Concentration is now <u>100mg/mL</u> <p>IV Infusion</p> <ul style="list-style-type: none"> • Reconstitute the vial (1g) with 9.4mL of Water for Injections • Shake to dissolve. The solution will fizz and become clear in 1 to 2 minutes. • Concentration is now 100mg/mL • Take 4mL (400mg) of the above solution and add 6mL of a compatible fluid. Final volume is 10mL • Final concentration is now <u>40mg/mL</u>
Administration	<p>IV Injection: Inject slowly over 3 to 5 minutes</p> <p>IV Infusion: Infuse over 15 to 30 minutes. Maximum concentration is 40mg/mL</p>
Adverse Reactions	Diarrhoea , rash , elevated hepatic transaminases, positive Coomb's test, eosinophilia, colitis
Storage	Reconstituted solution is stable for 12 hours at room temperature IV Infusion solution is stable for 24 hours at room temperature
Notes	Solution will effervesce on reconstitution. Excess bubbles must be expelled prior to use.

References	<p>Truven Health Analytics. Ceftazidime. In: NeoFax [Internet]. Greenwood Village (CO): Truven Health Analytics; 2019 [cited 2019 Oct 22]. Available from: https://neofax.micromedexsolutions.com/</p> <p>Lexicomp. Ceftazidime. In: UpToDate [Internet]. Alphen aan den Rijn (Netherlands): Wolters Kluwer; 2019 [cited 2019 oct 22]. Available from: https://www.uptodate.com/</p> <p>Society of Hospital Pharmacists of Australia. Ceftazidime. In: Australian Injectable Drugs Handbook [Internet]. [St Leonards, New South Wales]: Health Communication Network; 2019 [cited 2019 Oct 22]. Available from: http://aidh.hcn.com.au</p>
-------------------	---

Document owner:	Head of Department - Neonatology		
Author / Reviewer:	KEMH & PCH Pharmacy / Neonatology Directorate		
Date first issued:	August 2008	Version:	3.2
Last reviewed:	October 2019	Next review date:	Oct 2022
Endorsed by:	Neonatal Directorate Management Group	Date:	Oct 2019
Standards Applicable:	NSQHS Standards: 1  Governance, 3  Infection Control, 4  Medication Safety		

Printed or personally saved electronic copies of this document are considered uncontrolled.

Access the current version from the WNHS website.

For any enquiries relating to this guideline, please email KEMH.PharmacyAdmin@health.wa.gov.au

© Department of Health Western Australia 2019